09:46 AM EDT, 10/06/2025 (MT Newswires) -- Amgen ( AMGN ) said Monday it launched AmgenNow, a direct-to-patient program in the US starting with its cholesterol drug Repatha, or evolucumab.

The company said eligible patients can buy Repatha through the program for $239 per month, about 60% lower than the drug's current list price. The program is open to patients who are uninsured, in high-deductible health plans, or prefer to pay out of pocket, according to Amgen ( AMGN ).

The program will be available to all Repatha patients, including those on Medicare and Medicaid, and will not require step therapy or prior authorization, the company said.

Price: 297.00, Change: -0.89, Percent Change: -0.30